SOAP Note: 29-Year-Old Male – Alpha-Stim Reassessment with New Low Back Pain
Subjective
Chief Complaint: Reassessment of Alpha-Stim therapy; new onset low back pain
History of Present Illness:
- Alpha-Stim therapy: Patient reports Alpha-Stim has been "wonderful" for managing anxiety, depression, and insomnia 1, 2
- Side effects: Denies dizziness, headache, or skin irritation 2
- Overall health: No new changes reported
- Low back pain:
Mental Status (Audio-Only Telehealth):
- Speech: Coherent
- Thought process: Appropriate
Objective
Telehealth Limitations: Audio-only visit limits physical examination 3
Mental Status Examination:
- Speech: Normal, coherent
- Thought process: Organized and appropriate
- Mood: Appears improved on Alpha-Stim therapy 2
Physical Examination: Unable to perform comprehensive musculoskeletal examination via audio-only format 3
Assessment
Anxiety, depression, and insomnia – well-controlled on Alpha-Stim cranial electrotherapy stimulation
- Patient demonstrates sustained clinical response to Alpha-Stim therapy, consistent with evidence showing 47.8% remission rates at 24 weeks in GAD patients 2
- No adverse effects reported, which aligns with the well-tolerated safety profile of CES 1, 2
- Continue current regimen given excellent symptomatic control 2
Acute mechanical low back pain (approximately 4 weeks duration)
- Likely nonspecific low back pain based on mechanism of injury (improper bending/calisthenics) and absence of red flag symptoms 3
- No radicular symptoms reported (no radiation below knee, no neurological deficits) 3, 4
- Duration <6 weeks suggests acute phase where conservative management is appropriate 3
- Red flags absent: No bowel/bladder dysfunction, no progressive neurological deficits, no saddle anesthesia 3, 4
- Important consideration: Depression and insomnia (though currently controlled) can amplify pain perception and complicate low back pain recovery 5, 6
Plan
Alpha-Stim Therapy
- Continue current Alpha-Stim regimen given excellent therapeutic response for anxiety, depression, and insomnia 1, 2
- Maintain daily use as prescribed (typically 60 minutes per day) 2
- Continue monitoring for any delayed adverse effects, though none reported to date 2
- Schedule routine follow-up in 3 months for ongoing reassessment 2
Acute Low Back Pain Management
Immediate Management (First 4 Weeks):
- No imaging indicated at this time – routine radiography or advanced imaging (MRI/CT) is not recommended for nonspecific low back pain without red flags 3
- NSAIDs: Initiate trial of NSAIDs for pain control 3, 7
- Activity modification: Advise against complete bed rest; encourage return to normal activities as tolerated 3
- Self-care education: Provide guidance on proper body mechanics, lifting techniques, and stretching exercises 3
Reassessment Strategy:
- Schedule in-person or video visit in 2-4 weeks to perform comprehensive physical examination including:
- If symptoms persist beyond 4-6 weeks without improvement: Consider physical therapy referral and reassess for need for imaging 3, 7
- Immediate imaging only warranted if: Severe or progressive neurological deficits develop, bowel/bladder dysfunction, or other red flag symptoms emerge 3, 4
Patient Education – Red Flags Requiring Urgent Evaluation:
- Bowel or bladder dysfunction (urinary retention has 90% sensitivity for cauda equina syndrome) 4
- Rapidly progressive weakness or foot drop 4
- Saddle anesthesia 3, 4
- Severe or worsening pain despite conservative measures 3
Psychosocial Considerations:
- Monitor for pain-related mood changes: Given history of depression and anxiety, assess whether back pain impacts mental health at follow-up 5, 6
- Emphasize continued Alpha-Stim use: Maintaining control of depression and insomnia is critical, as both conditions can worsen pain perception and delay recovery from low back pain 5, 6
- The interplay between multisite pain and insomnia significantly increases risk of anxiety/depression recurrence (RR 2.42) 6